Kidney Cancer: Highlights from 2006 Francesco Montorsi  European Urology Supplements  Volume 6, Issue 12, Pages 745-753 (July 2007) DOI: 10.1016/j.eursup.2007.03.014 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 The size of renal cell carcinomas (RCCs) correlates with advanced stage (≥ pT3a) [9]. European Urology Supplements 2007 6, 745-753DOI: (10.1016/j.eursup.2007.03.014) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Although, a gradual increase in the percentage of partial nephrectomy (PN) has been observed in 1988–1989 and 2000–2001, it remains a relatively uncommon procedure, even in small size renal cell carcinomas (RCCs) [11]. European Urology Supplements 2007 6, 745-753DOI: (10.1016/j.eursup.2007.03.014) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Both operation time and estimated blood loss are significantly higher for laparoscopic partial nephrectomy (LPN) compared to laparoscopic cryoablation (LCA) [18]. European Urology Supplements 2007 6, 745-753DOI: (10.1016/j.eursup.2007.03.014) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 4 Results from interactive voting indicate that partial nephrectomy (PN), either open or laparoscopic, is the favoured treatment option for the given case (details are outlined in the text). Surprisingly, open or laparoscopic radical nephrectomy (RN) is still a frequently chosen treatment strategy. None of the participants chose another minimally invasive (MI) technique as treatment option. European Urology Supplements 2007 6, 745-753DOI: (10.1016/j.eursup.2007.03.014) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 5 The objective response rate in patients with advanced renal cell carcinoma is higher after sunitinib treatment compared with interferon-α (IFN-α) treatment [30]. European Urology Supplements 2007 6, 745-753DOI: (10.1016/j.eursup.2007.03.014) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 6 Temsirolimus (Temsr) treatment of patients with advanced renal cell carcinoma generates a significant increase in median survival compared to interferon-α (IFN-α) treatment, whereas no significant increase was observed with the combination therapy (Temsr+IFN-α) [39]. European Urology Supplements 2007 6, 745-753DOI: (10.1016/j.eursup.2007.03.014) Copyright © 2007 European Association of Urology Terms and Conditions